letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...5253545556575859606162...100101»
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg.
    Enrollment change, Trial completion date, Trial primary completion date:  TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov) -  Jan 8, 2021   
    P3,  N=309, Recruiting, 
    LE co-administration may prove to be highly effective in preventing OHSS, even in the women who are at high risk to these dangerous complications. N=144 --> 309 | Trial completion date: Nov 2020 --> Jan 2022 | Trial primary completion date: Nov 2020 --> Jan 2022
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Journal:  Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome. (Pubmed Central) -  Jan 1, 2021   
    Here, we treated Sprague Dawley rats with the aromatase inhibitor, letrozole, to increase the endogenous testosterone level and to decrease the estradiol levels...Our results show that an elevated endogenous testosterone level can induce hepatic steatosis. Decreasing the endogenous testosterone level in hepatocytes may represent a new approach in the treatment of NAFLD in PCOS patients.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    [VIRTUAL] Evaluating rates of neutropenia with Ibrance therapy adjustments based on day 15 labs. () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_3811;    
    The primary endpoint is the incidence of guidelines discordant dose adjustments made by prescribers based on day 15 labs. The secondary endpoints are percentage of Ibrance prescriptions filled at this institution, incidence of adverse effects (grade 3 and 4 neutropenia, nausea, vomiting, fatigue), patient outcomes (duration of therapy and disease progression) and incidence of guideline discordant dose adjustments among different regimens (Ibrance/letrozole, Ibrance/anastrazole, Ibrance/fulvestrant).
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion, Combination therapy:  Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer (clinicaltrials.gov) -  Dec 23, 2020   
    P2,  N=162, Completed, 
    The secondary endpoints are percentage of Ibrance prescriptions filled at this institution, incidence of adverse effects (grade 3 and 4 neutropenia, nausea, vomiting, fatigue), patient outcomes (duration of therapy and disease progression) and incidence of guideline discordant dose adjustments among different regimens (Ibrance/letrozole, Ibrance/anastrazole, Ibrance/fulvestrant). Active, not recruiting --> Completed
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Letrozole- a controversial drug for OHSS prevention? (Pubmed Central) -  Dec 20, 2020   
    We believe these findings will help medical personnel manage the side effects of many medications. No abstract available
  • ||||||||||  letrozole / Generic mfg., everolimus / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov) -  Dec 19, 2020   
    P1,  N=37, Completed, 
    No abstract available Active, not recruiting --> Completed | Trial completion date: Jul 2021 --> Dec 2020 | Trial primary completion date: Jul 2021 --> Dec 2020
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal, IO Biomarker:  Dendrobium nobile Lindl. polysaccharides improve follicular development in PCOS rats. (Pubmed Central) -  Dec 18, 2020   
    polysaccharides (DNLP) on ovarian follicular development in letrozole-induced PCOS rats and explored the underlying molecular mechanisms...DNLP exerted its protective effects via improving follicular development and inhibiting apoptosis of ovarian granular cells in PCOS rats. This study will provide experimental basis for the future clinical application of DNLP in the treatment of PCOS.
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Journal:  Aromatase Inhibition Ameliorates Decreased LH Output Found in Obese Women. (Pubmed Central) -  Dec 18, 2020   
    Letrozole (2.5-5 mg) was given daily to 22 women, 12 obese and 10 normal weight, for 7 days...The increase in LH pulse amplitude indicates that the AI effect is mediated at the level of the pituitary. Our results suggest that the hypogonadotropic phenotype of simple obesity is subject to modulation by interruption of estradiol negative feedback.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  MiRNAs expression profiling of rat ovaries displaying PCOS with insulin resistance. (Pubmed Central) -  Dec 18, 2020   
    These results indicate that differentially expressed miRNAs in rat ovaries may be involved in the pathophysiology of insulin resistance in PCOS. Our study may be beneficial in establishing miRNAs as novel diagnostic and therapeutic biomarkers for insulin resistance in PCOS.
  • ||||||||||  letrozole / Generic mfg.
    Biomarker, Review, Journal:  Predictive factors for intrauterine insemination outcomes: a review. (Pubmed Central) -  Dec 17, 2020   
    Our study may be beneficial in establishing miRNAs as novel diagnostic and therapeutic biomarkers for insulin resistance in PCOS. Providers recommending IUI for treatment of infertility should take into account all of these factors when evaluating patients and making treatment recommendations.
  • ||||||||||  PF-06804103 / Pfizer
    Trial completion date, Trial primary completion date:  PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) -  Dec 17, 2020   
    P1,  N=148, Recruiting, 
    Although more clinical studies are needed, letrozole is recommended for women with polycystic ovaries and those resistant to clomiphene citrate. Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024
  • ||||||||||  sacibertinib (Hemay022) / Tianjin Hemay Pharma
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer (clinicaltrials.gov) -  Dec 11, 2020   
    P1,  N=48, Recruiting, 
    In conclusion, early monitoring serum estradiol is an independent predicting factor for supraphysiologic level of serum estradiol on hCG triggering day in the COS cycles using letrozole and gonadotropins. Trial completion date: Jul 2019 --> Jul 2021 | Trial primary completion date: Mar 2019 --> Feb 2021